Your partner in oncology


Oncology Therapeutic Development

100 rue Martre
92110 Clichy - FRANCE
Tel:  +33 1 47 15 01 01
Fax: +33 1 45 19 06 59

Contact Us

Oncology Publications 2000-2011


  • Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.Serova M, Bieche I, Sablin MP, Pronk GJ, Vidaud M, Cvitkovic E, Faivre S, Raymond E. Br J Cancer. 2011;104(2):272-80.
  • Lovejoy KS, Serova M, Bieche I, Emami S, D'Incalci M, Broggini M, Erba E, Gespach C, Cvitkovic E, Faivre S, Raymond E, Lippard SJ. Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther. 2011;10(9):1709-19.
  •  Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA, Emami S, Vidaud D, Hammel P, Theu-Anton N, Gespach C, Faivre S, Raymond E. Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cß Inhibitor Enzastaurin in Colon Cancer Cells. Mol Cancer Ther. 2010 May;9(5):1308-17.
  • Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, Vidaud M, Phillips E, Weill S, Benhadji KA, Lokiec F, Cvitkovic E, Faivre S, Raymond E. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res. 2009 May 15; 69(10):4260-9.
  • Nowotnik DP, Cvitkovic E. ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic. Adv Drug Deliv Rev. 2009 Nov 12;61(13):1214-9 . Review.
  • Serova  M, Ghoul A, Rezai K, Lokiec F, Cvitkovic E, Nowotnik D, Faivre S and Raymond E. In vitro Antiproliferative. Effects of ProLindac™, a Novel Dach-Platinum-Linked Polymer Compound, as a Single Agent and in Combination with Other Anti-cancer Drugs Chapter in book “Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy”, Humana Press, 2009, P.41-48.
  • Tredaniel J, Becht C, Bekradda M, De Cremoux H, Alexandre J, Chomy F, Szyldergemain S, Yataghene Y, Culine S. An Open Phase II Trial of Gemcitabine, Oxaliplatin and Vinorelbine Combination as First-Line Therapy in advanced Non-Small Cell Lung Cancer Patients. Lung Cancer 2009; 63 (2): 259-263
  •  Serova M , Ghoul A, Benhadji KA, Faivre S, Le Tourneau C, Cvitkovic E, Lokiec F, Lord J, Ogbourne SM, Calvo F,  Raymond E. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther. 2008 Apr; 7(4):915-22.
  • Le Tourneau C, Faivre S, Serova M, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer. 2008 Oct 21; 99(8):1197-203.
  • Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer. 2008 Dec 2; 99(11):1808-15.
  • Serova M , Galmarini CM, Ghoul A, Benhadji K, Green SR, Chiao J, Faivre S, Cvitkovic E, Le Tourneau C, Calvo F, Raymond E. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3; 97(5):628-36.
  • Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol. 2007 Oct 2.
  • Alexandre J, Kahatt C, Bertheault-Cvitkovic F, Faivre S, Shibata S, Hilgers W, Goldwasser F, Lokiec F, Raymond E, Weems G, Shah A, MacDonald JR, Cvitkovic E. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Invest New Drugs. 2007 Oct; 25(5):453-62.
  • Ghoul A, Serova M, Le Tourneau C, Aissat N, Hammel P, Raymond E, Faivre S. Role of the endothelins and endothelin receptors in cancer cell signaling and angiogenesis. Targeted Oncology. 2007. V. 2: 181-191.
  • Mitry E, Ducreux M, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol. 2006 Mar;30(3):357-63 .
  • Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, Serin D, Tigaud JD, Eymard JC, Simon H, Bertaux B, Brienza S, Cvitkovic E. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Anticancer Drugs. 2006 Mar; 17(3):337-43.
  • Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol. 2006 Mar; 17(3):429-36.
  • Serova M , Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol. 2006 Apr; 57(4):491-9.
  • Hilgers W, Faivre S, Chieze S, Alexandre J, Lokiec F, Goldwasser F, Raymond E, Kahatt C, Taamma A, Weems G, MacDonald JR, Misset JL, Cvitkovic E. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Invest New Drugs. 2006 Jul; 24(4):311-9. 12.
  • Serova M , Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol. 2006 Aug; 33(4):466-78. Review.
  • Voland C, Bord A, Peleraux A, Penarier G, Carriere D, Galiegue S, Cvitkovic E, Jbilo O, Casellas P. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther. 2006 Sep; 5(9):2149-57.
  • Delozier T, Guastalla JP, Yovine A, Levy C, Chollet P, Mousseau M, Delva R, Coeffic D, Vannetzel JM, Zazzi ES, Brienza S, Cvitkovic E. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracyclinepretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs. 2006 Oct; 17(9):1067-73.
  • Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, Lokiec F. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. Drug Metab Dispos. 2006 Nov; 34(11):1918-26.
  • Ghoul A, Serova M, Benhadji KA, Cvitkovic E, Faivre S, Philips E, Calvo F, Lokiec F, Raymond E. Protein Kinase C a & d Are Members of a Large Kinase Family of High Potential for Novel Anticancer Targeted Therapy. Targeted oncology. 2005. N1, p. 34-47.
  • Raymond E, Kahatt C, Rigolet MH, Sutherland W, Lokiec F, Alexandre J, Tombal B, Elman M, Lee MS, MacDonald JR, Cullen M, Misset JL, Cvitkovic E. Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials. Clin Cancer Res. 2004 Nov 15;10(22):7566-74. Erratum in: Clin Cancer Res. 2005 Feb 15; 11(4):1684.
  • Serova  M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol. 2005 Aug 2; 57(4):491-9
  • Ma L, Serova M, Podgorniak MP, Berthois Y, Mourah S, Calvo F. Amphiregulin antisense RNA expression inhibits angiogenesis of human breast cancer in nude mice. Zhonghua Zhong Liu Za Zhi. 2005 Sep; 27(9):521-3.
  • Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol. 2004 Mar; 15(3):467-73.
  • Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E , Misset JL. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004 Mar 1;22(5):890-9.
  • Alexandre J, Raymond E, Kaci MO, Brain EC, Lokiec F, Kahatt C, Faivre S, Yovine A, Goldwasser F, Smith SL, MacDonald JR, Misset JL, Cvitkovic E. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin Cancer Res. 2004 May 15; 10(10):3377-85.
  • Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazze S, Bruzzi P, Gatta G, Molinari R. Cancer of the nasopharynx. Crit Rev Oncol Hematol. 2003 Feb; 45(2):199-213. Review.
  • Urien S, Alexandre J, Raymond E, Brain E, Smith S, Shah A, Cvitkovic E, Lokiec F. Phase I population pharmacokinetics of irofulven. Anticancer Drugs. 2003 Jun; 14(5):353-8.
  • Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E, Benoit G. Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol. 2003 Aug; 14(8):1291-8.
  • Poindessous V, Koeppel F, Raymond E, Cvitkovic E, Waters SJ, Larsen AK. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. Int J Oncol. 2003 Nov; 23(5):1347-55.
  • Mita C, Chatelut E, Bekradda M, Soulie P, Canal P, Misset JL, Cvitkovic E, Bugat R. Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies. Annals Oncology 14. 2003;14(12):1776-82.
  • Menashi S, Serova M, Ma L, Vignot S, Mourah S, Calvo F. Regulation of Extracellular Matrix Metalloproteinase Inducer and Matrix Metalloproteinase Expression by Amphiregulin in Transformed Human Breast Epithelial Cells. Cancer Research. 2003. V.63 (22). P. 7575-7580.
  • Monnet I, de CH, Soulie P, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Annals of Oncology 13. 2002 Jan; 13(1):103-7.
  • Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Mol Cancer Ther. 2002 Jan; 1(3):227-35. Review.
  • Boisdron-Celle M, Craipeau C, Brienza S, Delva R, Guerin-Meyer V, Cvitkovic E, Gamelin E. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol. 2002 Mar; 49(3):235-43. Epub 2002 Jan 16.
  • Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002 Mar 15;20(6):1512-8.
  • Gornet JM, Savier E, Lokiec F, Cvitkovic E, Misset JL, Goldwasser F. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol. 2002 Aug; 13(8):1315-8 .
  • Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjonnfjord G, Bekradda M, Itzhaki M, Herait P. Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One prior Chemotherapy Regimen Has Failed. Journal of Clinical Oncology 20 (1): 205-213, 2002.
  • Laurence V, Faivre S, Vera K, Pierga JY, Delbado C, Bekradda M, Armand JP, Gianella-Borradori A, Dieras V, Raymond E. Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel cyclindependent kinases inhibitor, in patients with advanced malignancies. European Journal 38 (suppl 7): 49, 2002.
  • Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002 Dec 1; 20(23):4543-8.
  • Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, Rosing H, Jimeno JM, Cvitkovic E . Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001 Mar 1;19(5):1256-65.
  • Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol. 2001 Mar 1;19(5):1248-55.
  • Cvitkovic E , Bekradda M, Essassi D, Noble-Kempin S. DNA-binding agents: Oxaliplatin (Eloxatine). Outline of Oncology Therapeutics: 19, 2001. Ratain, Tempero, Skosey. W.B Saunders Company [book chapter].
  • Cvitkovic E , Bekradda M, Essassi D, Beth Mardjetko M. Antimicrotubule agents: Vindesine (Eldesine). Outline of Oncology Therapeutics: 24, 2001. Ratain, Tempero, Skosey. W.B Saunders Company [book chapter].
  • Becouarn Y, Gamelin E, Coudert B, Negrier S, Pierga JY, Raoul JL, Provencal J, Rixe O, Krisch C,
  • Germa C, Bekradda M, Mignard D, Mousseau M. Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients. Journal of Clinical Oncology 19 (22): 4195-4201, 2001.
  • Laadem A, Cvitkovic E. Oxaliplatin: a first DACH-platinum in oncology. Bull Cancer. 2001 Aug; 88 Spec No: S9-13. Review. French.
  • Bensmaine MA, Marty M, de Gramont A, Brienza S, Levi F, Ducreux M, Francois E, Gamelin E, Bleiberg H, Cvitkovic E. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer. 2001 Aug 17; 85(4):509-17.
  • Sparidans RW, Rosing H, Hillebrand MJ, Lopez-Lazaro L, Jimeno JM, Manzanares I, van Kesteren C, Cvitkovic E , van Oosterom AT, Schellens JH, Beijnen JH. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anticancer Drugs. 2001 Sep; 12(8):653-66.
  • Monnet I, Soulie P, de Cremoux H, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Dupont-Andre G, Cvitkovic E. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. 19(2):458-63, 2001.
  • Wasserman E, Sutherland W, Cvitkovic E. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer. Clin Colorectal Cancer. 2001 Nov; 1(3):149-53. Review.
  • van Kesteren C, Mathjt RA, Lopez-Lazaro L, Cvitkovic E, Taamma A, Jimeno JM, Guzman C, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemother Pharmacol. 2001 Dec; 48(6):459-66.
  • Kempen I., Pochet L., Doucet C., Lacan F., Bourdel F., Reboud-Ravaux M., Noel A., Foidart J-M., Pirotte B. Inhibition of cancer cells invasion by coumarin derivatives. Scientific Meeting of the Belgian Association for Cancer Research – Invasion and Metastasis, January 29, 2000, Ghent – Belgium
  • Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand JP, Simon J, Cvitkovic E . Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol. 2000 Mar;18(6):1324-30.
  • Fizazi K, Caliandro R, Soulie P, Fandi A, Daniel C, Bedin A, Doubre H, Viala J, Rodier J, Trandafir L, Le Chevalier T, Cvitkovic E, Armand J, Ruffie P. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer. 2000 Aug; 36(12):1514-21.
  • Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol. 2000 Aug;35(2):75-93. Review.
  • Bourdel F. , Lacan F., Doucet C., Pochet L., Caflish A., Masereel B., Pirotte B., Reboud-Ravaux M.: Oxobenzopyran derivatives as thrombin inhibitors, XVI International Symposium on Medicinal Chemistry, September 18-22, 2000, Bologna – Italy
  • Goldwasser F, Gross-Goupil M, Tigaud JM, Di Palma M, Marceau-Suissa J, Wasserman E, Yovine A, Misset JL, Cvitkovic E. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. Ann Oncol. 2000 Nov;11(11):1463-70.
  • van Kesteren C, Cvitkovic E, Taamma A, Lopez-Lazaro L, Jimeno JM, Guzman C, Math RA, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res. 2000 Dec;6(12):4725-32.
  • Hasbini A, Durdux C, Faivre S, Wasserman E, Taamma A, Armand JP, Raymond E, Cvitkovic E. [Epidermoid carcinoma of the head and neck: contribution of chemotherapy in case of recurrence and locally advanced disease. Review of the literature. Ann Otolaryngol Chir Cervicofac. 2000 Dec;117(6):390-402. Review. French.
  • Bensmaine, de Gramont A, Brienza S, Marty M, Levi F, Ducreux M, Francois E, Gamelin E, Bleiberg H, Bleuzen P, Simon J, Cvitkovic E. Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. Eur J Cancer. 2000 Dec;36(18):2335-43.
  • Delaloge S, Laadem A, Taamma A, Chouaki N, Cvitkovic E, Pautier P, Misset JL, Lhomme C. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol. 2000 Dec;23(6):569-74.
  • Hasbini A, Raymond E, Cvitkovic E, Eschwege F, Armand JP. Carcinoma of the nasopharynx. Bull Cancer. 2000 Dec;Suppl 5:21-6. Review. French.